Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,570 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metabolic and Nutritional Complications Clear all
Completed Not applicable Interventional

Using Early Time Restricted Feeding and Timed Light Therapy to Improve Glycemic Control in Adults With Type 2 Diabetes

NCT04155619
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Time Restricted Feeding, Light; Therapy, Complications
Interventions
No change in meal timing, No change in light exposure, Early Time-Restricted Feeding, Timed Light Therapy
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
30 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Not applicable Interventional

Feasibility and Validation of a Smart Changing Pad for Home Infant Weight Monitoring After Hospital Discharge

NCT07718516
View directory record Official record
Conditions
Infant Nutrition Disorders, Weight Loss, Postnatal Care, Premature Birth
Interventions
Woddle Smart Changing Pad
Device
Lead sponsor
Stan Kachnowski
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Not applicable Interventional

Preventing T2DM After GDM With Immediate Postpartum Screening

NCT06457139
View directory record Official record
Conditions
Gestational Diabetes, Type 2 Diabetes
Interventions
Glucose tolerance test (2 hour), Active Comparator
Diagnostic Test · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 15, 2026, 2:45 AM EDT
Completed No phase listed Observational

Real-world Aliskiren Use in Diabetic Patients

NCT01393860
View directory record Official record
Conditions
Diabetes, Hypertension
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Oct 15, 2026, 2:45 AM EDT
Recruiting Phase 4 Interventional

Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity

NCT06699810
View directory record Official record
Conditions
Ketosis Prone Diabetes
Interventions
Continuous Glucose Monitoring, Insulin
Device · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 15, 2026, 2:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Testing Glial Pathways to HAAF in Human Subjects Using Carbon 13 Magnetic Resonance Spectroscopy

NCT02690168
View directory record Official record
Conditions
Diabetes Complications, Hypoglycemia
Interventions
Fasting
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study With SNF472 in Calciphylaxis Patients

NCT02790073
View directory record Official record
Conditions
Calciphylaxis, Calcific Uremic Arteriolopathy
Interventions
SNF472
Drug
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Waltham, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 15, 2026, 2:45 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

PCOS & Insulin Resistance Exercise Study

NCT02303470
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Insulin Resistance
Interventions
Vigorous Exercise, Moderate Exercise
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Not applicable Interventional

Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Funduscopic Images

NCT05857943
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy
Interventions
AEYE-DS Software
Device
Lead sponsor
AEYE Health Inc
Industry
Eligibility
22 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Fayetteville, Arkansas • Orlando, Florida • Jackson, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 15, 2026, 2:45 AM EDT
Not yet recruiting Not applicable Interventional

Menstruation and Anemia Research: A Community Health Study

NCT07832526
View directory record Official record
Conditions
Anemia
Interventions
Standard of Care, Informational Series and follow-up support
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 55 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metformin Compared to Glyburide in Gestational Diabetes

NCT00965991
View directory record Official record
Conditions
Gestational Diabetes
Interventions
metformin, Glyburide
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
13 Years and older · Female only
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Not applicable Interventional

Diabetes Prevention Among Post-partum Women With History of Gestational Diabetes

NCT02240420
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Life Style Counseling (Star-Mama)
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 15, 2026, 2:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)

NCT06839235
View directory record Official record
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Interventions
ABO-101
Drug
Lead sponsor
Arbor Biotechnologies
Industry
Eligibility
6 Years to 64 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2043
U.S. locations
2
States / cities
Rochester, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Phase 3 Interventional

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

NCT00044408
View directory record Official record
Conditions
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Ruboxistaurin mesylate
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
13
States / cities
Long Beach, California • Norwalk, Connecticut • Clearwater, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

NCT02962648
View directory record Official record
Conditions
Iron Deficiency Anemia, Iron Deficiency Anaemia
Interventions
Iron isomaltoside/ferric derisomaltose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Chula Vista, California • La Mesa, California • Northridge, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Phase 1 Interventional

SEAPORT 1: Study of INZ-701 in Adults With Hemodialysis-Dependent End-Stage Kidney Disease

NCT06283589
View directory record Official record
Conditions
Calciphylaxis
Interventions
INZ-701
Drug
Lead sponsor
Inozyme Pharma
Industry
Eligibility
18 Years to 69 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Coral Springs, Florida • Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 15, 2026, 2:45 AM EDT
Enrolling by invitation Not applicable Interventional

Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes

NCT06914726
View directory record Official record
Conditions
Hereditary Breast/Ovarian Cancer (brca1, brca2), Lynch Syndrome, Genetic Variation, HBOC Syndrome, Hereditary Cancer Syndromes
Interventions
Patient Centered Clinical Decision Support (PC-CDS)
Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
2,488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Not applicable Interventional

Feasibility Study for the Comprehensive Overweight/Obesity Management Pre-Kidney Transplant (COMPKT) Program

NCT06688825
View directory record Official record
Conditions
Kidney Transplant; Complications, Obesity
Interventions
Education regarding Weight loss, Lifestyle tools for weight loss, Blood draw
Behavioral · Biological
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 15, 2026, 2:45 AM EDT
Recruiting Phase 2 Interventional

Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS

NCT07138274
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
Interventions
Metyrapone 250 mg Oral Tablets, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Macrobiotic Diet and Flax Seed: Effects on Estrogens, Phytoestrogens, & Fibrinolytic Factors

NCT00010829
View directory record Official record
Conditions
Cardiovascular Diseases, Osteoporosis, Breast Cancer, Endometrial Cancer
Interventions
American Heart Association Step 1 diet, American Heart Association Step 2 diet + 10 g/day flax seed, Macrobiotic dietary intervention
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
50 Years to 72 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 15, 2026, 2:45 AM EDT
Terminated Not applicable Interventional

Insulin Differences Between African-American and Caucasian Female Adolescents With Polycystic Ovary Syndrome (PCOS)

NCT02052479
View directory record Official record
Conditions
Polycystic Ovary Syndrome, PCOS
Interventions
Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 15, 2026, 2:45 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence

NCT06721351
View directory record Official record
Conditions
Diabetic Retinopathy (DR)
Interventions
Diabetic Retinopathy screening Point of Care Artificial Intelligence
Diagnostic Test
Lead sponsor
Centro De Salud La Comunidad De San Ysidro Inc DBA: San Ysidro Health
Other
Eligibility
22 Years and older
Enrollment
548 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Chula Vista, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 15, 2026, 2:45 AM EDT
Active, not recruiting Phase 3 Interventional

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

NCT06297603
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
28
States / cities
Huntsville, Alabama • Sun City West, Arizona • Apple Valley, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Not applicable Interventional Results available

Calcitonin for Treating X-linked Hypophosphatemia

NCT01652573
View directory record Official record
Conditions
Hypophosphatemic Rickets, X Linked Dominant
Interventions
nasal salmon calcitonin, Saline Nasal Spray Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 15, 2026, 2:45 AM EDT